F064 The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients
DESCRIPTION
Dermatologists face multiple challenges when evaluating and treating the pregnant patient. Treatment of acne, atopic dermatitis and psoriasis is difficult; risks to the fetus limit the number of evidence-based studies concerning drug therapy. Concerning melanocytic lesions, do nevi change during pregnancy, and if melanoma is diagnosed, is there a poor prognosis? Infections and infestation may present a risk for mother and fetus, and treatment options may be limited. Several dermatoses are specific for pregnancy; early recognition and management may be important to prevent adverse effects on the fetus and/or mother.
LEARNING OBJECTIVES
Develop treatment plans for pregnant patients with common dermatologic diagnoses.
Evaluate and manage melanocytic lesions in the pregnant patient.
Recognize and treat specific dermatoses of pregnancy.
SCHEDULE
3:30 PM
Treatment of Psoriasis in the Pregnant Patient
Bruce Elliot Strober, MD, PhD, FAAD
3:50 PM
Treatment of Acne in the Pregnant Patient
Jonette Elizabeth Keri, MD, PhD, FAAD
4:10 PM
Specific Dermatoses of Pregnancy
Miriam Keltz Pomeranz, MD, FAAD
4:30 PM
Treatment of infections and Infestations in the Pregnant Patient
Jenny Eileen Murase, MD, FAAD
4:50 PM
Evaluation and Management of Nevi and Melanoma in the Pregnant Patient
Jane Margaret Grant-Kels, MD, FAAD
5:10 PM
Treatment of Atopic Dermatitis in the Pregnant Patient
Marcia S. Driscoll, MD, FAAD
DIRECTOR
Marcia S. Driscoll, MD, FAAD
SPEAKERS
Jane Margaret Grant-Kels, MD, FAAD
Jonette Elizabeth Keri, MD, PhD, FAAD
Jenny Eileen Murase, MD, FAAD
Miriam Keltz Pomeranz, MD, FAAD
Bruce Elliot Strober, MD, PhD, FAAD
HANDOUTS
DISCLOSURES
Marcia S. Driscoll, MD, FAAD
UpToDate, Inc – Other(Honoraria);
Jane Margaret Grant-Kels, MD, FAAD
No financial relationships exist with ineligible companies.
Jonette Elizabeth Keri, MD, PhD, FAAD
Almirall – Consultant(Fees); Galderma Mexico – Speaker(Honoraria); Galderma USA – Investigator(Grants/Research Funding); L'Oreal – Advisory Board(Honoraria); Ortho Dermatologics – Advisory Board(Honoraria); Primus Pharmaceuticals – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria);
Jenny Eileen Murase, MD, FAAD
AbbVie – Consultant(Honoraria), Speaker/Faculty Education(Honoraria); Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); Attovia Therapeutics – Consultant (1099 relationship)(Honoraria); Blueprint Medicines – Advisory Board(Honoraria); Blueprints Medicine – Speaker(Honoraria); Eli Lilly – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker/Faculty Education(Honoraria); Galderma – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Leo Pharma – Advisory Board(Honoraria); Leo Pharma Inc – Speaker/Faculty Education(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Speaker(Honoraria); Phothera – Advisory Board(Honoraria); Regeneron – Speaker/Faculty Education(Honoraria); Sanofi – Speaker(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); UCB – Advisory Board(Honoraria), Consultant(Honoraria), Speaker/Faculty Education(Honoraria); UpToDate – Consultant(Honoraria);
Miriam Keltz Pomeranz, MD, FAAD
Procter & Gamble Company – Advisory Board(Fees); UpToDate – Other(Patent royalties or other compensation for Intellectual Property Rights);
Bruce Elliot Strober, MD, PhD, FAAD
AbbVie – Advisory Board(Honoraria), Consultant(Honoraria), Speaker(Honoraria); Alumis – Consultant(Fees); Amgen – Consultant (1099 relationship)(Fees); Arcutis, Inc. – Consultant(Fees), Speaker(Honoraria); Boehringer Ingelheim – Consultant(Honoraria); Bristol Myers Squibb – Speaker(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria), Consultant(Fees); Connect Biopharma LLC – Stockholder(Other Financial Benefit); CoreEvitas, LLC – Advisory Board(Honoraria), Investigator(Fees); Eli Lilly and Company – Advisory Board(Honoraria), Consultant(Honoraria), Speaker(Honoraria); Johnson and Johnson – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees), Speaker(Honoraria); Leo Pharma Inc – Advisory Board(Honoraria), Consultant(Honoraria); Meiji Seika Pharma Co., Ltd – Consultant(Fees); Mindera – Stockholder(Other Financial Benefit); Novartis Pharmaceuticals Corp. – Advisory Board(Honoraria), Consultant(Honoraria); Oruka Therapeutics – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria), Consultant(Honoraria), Speaker(Honoraria); UCB – Advisory Board(Honoraria), Consultant(Fees), Speaker(Honoraria);